P16 Methylation as an Early Predictor for Cancer Development From Oral Epithelial Dysplasia: A Double-blind Multicentre Prospective Study

EBioMedicine

Volumn 2, Issue 5, 2015, Pages 432-437

  Liu, Hongwei ^a   Liu, Xue wei ^b   Dong, Guangying ^c   Zhou, Jing ^d   Liu, Yang ^a   Gao, Yan ^a   Liu, Xiao yong ^b   Gu, Liankun ^d   Sun, Zheng ^b   Deng, Dajun ^d  

^a PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Methylation; Oral dysplasia; P16; Prospective cohort; Transformation

Indexed keywords

PROTEIN P16; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; DISCOID LUPUS ERYTHEMATOSUS; DOUBLE BLIND PROCEDURE; EPITHELIUM DYSPLASIA; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN METHYLATION; CELL TRANSFORMATION; CLINICAL TRIAL; DEMOGRAPHY; DISEASE COURSE; DNA METHYLATION; EARLY CANCER DIAGNOSIS; EPITHELIUM CELL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOUTH TUMOR; MULTIVARIATE ANALYSIS; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

ADULT; AGED; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEMOGRAPHY; DISEASE PROGRESSION; DNA METHYLATION; DOUBLE-BLIND METHOD; EARLY DETECTION OF CANCER; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84949623418     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.03.015     Document Type: Article

References (30)

1. Arduino P.G., Surace A., Carbone M., et al. Outcome of oral dysplasia: a retrospective hospital-based study of 207 patients with a long follow-up. J. Oral Path. Med. 2009, 38(6):540-544.
2. Belinsky S.A., Liechty K.C., Gentry F.D., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006, 66(6):3338-3344.
3. Beroukhim R., Mermel C.H., Porter D., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463(7283):899-905.
4. Bouquot J.E., Gorlin R.J. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35years. Oral Surg. Oral Med. Oral Pathol. 1986, 61(4):373-381.
5. Bouquot J.E., Whitaker S.B. Oral leukoplakia-rationale for diagnosis and prognosis of its clinical subtypes or "phases". Quintessence Int. 1994, 25(2):133-140.
6. Cairns P., Polascik T.J., Eby Y., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 1995, 11(2):210-212.
7. Cao J., Zhou J., Gao Y., et al. Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. Clin. Cancer Res. 2009, 15(16):5178-5183.
8. Danahey D.G., Tobin E.J., Schuller D.E., Bier-Laning C.M., Weghorst C.M., Lang J.C. p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol. 1999, 119(2):285-288.
9. Deng D.J., Liu Z.J., Du Y.T. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Epigenet. Cancer Pt B 2010, 71:125-176.
10. Gale N., Westra W., Pilchy B.Z., et al. Epithelial precursors lesions. World Health Organization Classification of Tumors: Pathology and Genetics of Head and Neck Tumors 2005, 177-179. IARC Press, Lyon. L. Barnes, J.W. Eveson, P. Reichart (Eds.).
11. Gonzalez-Zulueta M., Bender C.M., Yang A.S., et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995, 55(20):4531-4535.
12. Hall G., Shaw R., Field E., et al. p16 promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol. Biomarkers Prev. 2008, 17(8):2174-2179.
13. Herman J.G., Merlo A., Mao L., et al. Inactivation of the CDKN2/P16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55(20):4525-4530.
14. Ho M.W., Risk J.M., Woolgar J.A., et al. The clinical determinants of malignant transformation in oral epithelial dysplasia. Oral Oncol. 2012, 48(10):969-976.
15. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat. Genet. 1994, 8(1):15-21.
16. Kannengiesser C., Brookes S., del Arroyo A.G., et al. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum. Mutat. 2009, 30(4):564-574.
17. Kramer I.R., Lucas R.B., Pindborg J.J., Sobin L.H. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg. Oral Med. Oral Pathol. 1978, 46(4):518-539.
18. Kresty L.A., Mallery S.R., Knobloch T.J., et al. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res. 2002, 62(18):5295-5300.
19. Liu L., Lassam N.J., Slingerland J.M., et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995, 11(2):405-412.
20. Liu Z.J., Zhang J., Gao Y.H., et al. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. Clin. Cancer Res. 2014, 20(17):4598-4612.
21. Luo D.Y., Zhang B.Z., Lv L.B., et al. Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. Lab. Invest. 2006, 86(6):591-598.
22. Merlo A., Herman J.G., Mao L., et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1995, 1(7):686-692.
23. Qin S., Li Q., Zhou J., et al. Homeostatic maintenance of allele-specific p16 methylation in cancer cells accompanied by dynamic focal methylation and hydroxymethylation. PLoS One 2014, 9(5):e97785.
24. Reed A.L., Califano J., Cairns P., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996, 56(16):3630-3633.
25. Riese U., Dahse R., Fiedler W., et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int. J. Mol. Med. 1999, 4(1):61-65.
26. Serrano J., Goebel S.U., Peghini P.L., Lubensky I.A., Gibril F., Jensen R.T. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J. Clin. Endocrinol. Metab. 2000, 85(11):4146-4156.
27. Sun Y., Deng D.J., You W.C., et al. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. Clin. Cancer Res. 2004, 10(15):5087-5093.
28. Widschwendter M., Siegmund K.D., Müller H.M., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004, 64(11):3807-3813.
29. Yu D.H., Waterland R.A., Zhang P., et al. Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice. J. Clin. Invest. 2014, 124(9):3708-3712.
30. Zhou J., Cao J., Lu Z., Liu H., Deng D. A 115-bp MethyLight assay for detection of p16 (CDKN2A) methylation as a diagnostic biomarker in human tissues. BMC Med. Genet. 2011, 12:67.